Burney Co. Sells 38,157 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Burney Co. cut its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 52.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 34,476 shares of the specialty pharmaceutical company’s stock after selling 38,157 shares during the period. Burney Co. owned 0.11% of Collegium Pharmaceutical worth $988,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. JPMorgan Chase & Co. grew its holdings in Collegium Pharmaceutical by 173.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company’s stock valued at $10,711,000 after buying an additional 175,892 shares during the last quarter. Penserra Capital Management LLC acquired a new stake in shares of Collegium Pharmaceutical in the third quarter worth $757,000. Barclays PLC increased its position in Collegium Pharmaceutical by 152.2% during the third quarter. Barclays PLC now owns 75,052 shares of the specialty pharmaceutical company’s stock worth $2,899,000 after acquiring an additional 45,291 shares during the period. Squarepoint Ops LLC raised its stake in Collegium Pharmaceutical by 194.5% during the 2nd quarter. Squarepoint Ops LLC now owns 110,338 shares of the specialty pharmaceutical company’s stock valued at $3,553,000 after purchasing an additional 72,874 shares during the last quarter. Finally, Marshall Wace LLP bought a new stake in Collegium Pharmaceutical in the 2nd quarter valued at $2,285,000.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. HC Wainwright restated a “buy” rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a report on Friday, January 10th. Needham & Company LLC raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price target for the company in a report on Friday, January 10th. Piper Sandler reiterated a “neutral” rating and issued a $37.00 price objective on shares of Collegium Pharmaceutical in a research report on Friday, October 11th. Finally, StockNews.com cut Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 23rd. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $43.80.

Insider Buying and Selling

In other news, EVP Shirley R. Kuhlmann sold 27,500 shares of the company’s stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $33.04, for a total value of $908,600.00. Following the sale, the executive vice president now owns 119,184 shares of the company’s stock, valued at approximately $3,937,839.36. This represents a 18.75 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 3.98% of the stock is owned by corporate insiders.

Collegium Pharmaceutical Stock Up 1.5 %

NASDAQ COLL opened at $33.46 on Friday. Collegium Pharmaceutical, Inc. has a 1-year low of $28.39 and a 1-year high of $42.29. The company has a market capitalization of $1.08 billion, a price-to-earnings ratio of 14.42 and a beta of 0.82. The stock’s 50 day moving average is $30.52 and its two-hundred day moving average is $34.09. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.